[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
February 1962

The Intralesional Use of Triamcinolone Acetonide in Psoriasis: A Double Blind Study

Author Affiliations


From the Department of Dermatology of the Northwestern University Medical Center (H. Rattner, M.D., Chairman) and the Department of Medicine (Dermatology) of the Veterans Administration Research Hospital.

Arch Dermatol. 1962;85(2):258-260. doi:10.1001/archderm.1962.01590020098010

The effectiveness of the treatment of psoriatic lesions by the intralesional injections of triamcinolone acetonide has been demonstrated by many investigators.1-3 In a double blind study of psoriatic patients triamcinolone acetonide by intralesional injection was indeed found to be effective in clearing the lesion of psoriasis. Its efficacy was markedly greater than hydrocortisone or prednisolone tertiary butyl acetate.

Material and Method  All patients in this study were hospitalized and had no other form of systemic or topical therapy. In order to avoid the possibility of systemic effect the amount of triamcinolone acetonide injected was limited to 0.2 ml. of 1% suspension. The control material was the vehicle alone to which hydrocortisone acetate was added to make a 0.4% suspension to simulate the cloudy appearance of the triamcinolone acetonide suspension. Hydrocortisone acetate in this concentration was found to be totally ineffective in the treatment of psoriatic plaques. The suspensions were